Volume 11, Number 1—January 2005
Research
Hepatitis C Virus Infection, Linxian, China1
Table
Prevalence of anti-HCV (by RIBA), HBsAg, and HBcAb in Linxian in 2000*
N (%) | Anti-HCV % (95% CI) | p | HBcAb % (95% CI) | p | HBcAb and HBsAg % (95% CI) | p | |
---|---|---|---|---|---|---|---|
Overall | 9.6 (7.0–12.2) | 54.6 (50.2-59.0) | 6.4 (4.3-8.5) | ||||
Age in 2000 (y) | |||||||
<59 | 166 (33.2) | 8.4 (4.2–12.7) | 53.6 (46.0–61.2) | 5.4 (2.0–8.9) | |||
60–64 | 105 (21.0) | 13.3 (6.8–19.8) | 50.5 (40.9–60.0) | 6.7 (1.9–11.4) | |||
65–69 | 90 (18.0) | 11.1 (4.6–17.6) | 50.0 (39.7–60.3) | 4.4 (0.2–8.7) | |||
70–74 | 82 (16.4) | 6.1 (0.9–11.3) | 62.2 (51.7–72.7) | 8.5 (2.5–14.6) | |||
>75 | 57 (11.4) | 8.8 (1.4–16.1) | 0.50 | 61.4 (48.8–74.0) | 0.34 | 8.8 (1.4–16.1) | 0.73 |
Sex | |||||||
Male | 200 (40.0) | 9.5 (5.4–13.6) | 58.0 (51.2–64.8) | 5.0 (2.0–8.0) | |||
Female | 300 (60.0) | 9.7 (6.3–13.0) | 0.95 | 52.3 (46.7–58.0) | 0.21 | 7.3 (4.4–10.3) | 0.18 |
Commune | |||||||
Yaocun | 170 (34.0) | 11.8 (6.9–16.6) | 53.5 (46.0–61.0) | 6.5 (2.8–10.2) | |||
Rencun | 95 (19.0) | 14.7 (7.6–21.9) | 64.2 (54.6–73.8) | 6.3 (1.4–11.2) | |||
Donggang | 116 (23.2) | 2.6 (0.0–5.5) | 53.5 (44.4–62.5) | 6.0 (1.7–10.4) | |||
Hengshui | 119 (23.8) | 9.2 (4.0–14.4) | 0.02 | 49.6 (40.6–58.6) | 0.18 | 6.7 (2.2–11.2) | 0.50 |
*HCV, hepatitis C virus; RIBA, recombinant immunoblot assay; HBsAg, hepatitis B surface antigen; HBcAb, hepatitis B core antibody; CI, confidence interval.
1Presented in part at the 11th Triennial International Symposium on Viral Hepatitis and Liver Disease, Sydney, Australia, April 4–10, 2003.